Structure Therapeutics Slides 28% This Year as $6 Million Stake Emerges

On February 17, 2026, B Group, Inc. disclosed a new position in Structure Therapeutics (NASDAQ:GPCR), acquiring 90,000 shares in the fourth quarter.B Group disclosed in a Securities and Exchange Commission (SEC) filing dated February 17, 2026, that it initiated a new position in Structure Therapeutics (NASDAQ:GPCR) by purchasing 90,000 shares. The quarter-end value of the stake stood at $6.26 million, reflecting pricing as of December 31, 2025.Structure Therapeutics is a clinical-stage biotechnology company specializing in the development of novel oral small molecule therapeutics for chronic diseases with significant unmet needs. The company leverages proprietary expertise in targeting GPCRs to advance a pipeline of differentiated drug candidates, including GSBR-1290 for type-2 diabetes and obesity, and additional programs for pulmonary and cardiovascular indications. With a focus on innovation in oral therapeutics, Structure Therapeutics aims to address large, underserved patient populations and establish a competitive edge in the biopharmaceutical sector.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool